Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Ment Health Subst Use. 2014 Mar 6;7(4):420–430. doi: 10.1080/17523281.2014.892897

Table 3.

Associations between participant symptom complaints at 12-month follow-up and randomization into the contingency management intervention (n = 104)a

Somatization
b (95% CI)		 Obsessive-Compulsive
b (95% CI)		 Interpersonal Sensitivity
b (95% CI)		 Depression
b (95% CI)		 Anxiety
b (95% CI)		 Hostility
b (95% CI)		 Phobic Anxiety
b (95% CI)		 Paranoid Ideation
b (95% CI)		 Psychoticism
b (95% CI)
CM Intervention −0.32* ([−0.62] – [−0.01]) −0.40** ([−0.70] – [−0.11]) −0.38* ([−0.71] – [−0.05]) −0.40* ([−0.73] – [−0.06]) −0.45** ([−0.76] – [−0.14]) −0.38* ([−.74] – [−0.02]) −0.44* ([−0.80] – [−0.09]) −0.61*** ([−0.94] – [−0.29]) −0.55** ([−0.93] – [−0.17])
R2 0.26 0.23 0.25 0.22 0.38 0.17 0.23 0.36 0.26
a

nControl = 49; nCM = 55

*

≤ 0.05;

**

p ≤ 0.01;

***

p ≤ 0.001; all sig. tests 2-tailed

Statistical controls: Substance abstinence during intervention phase (urinalysis/breathalyzer confirmed), baseline symptom complaints (domain-specific), participant race/ethnicity, age, and HIV status

CM Omnibus test of significance (i.e., contingency management intervention b = 0 across all symptom domains): χ2(9) = 17.26; p < 0.05